

Guillermo J Ruiz-Argente

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6862191/publications.pdf>

Version: 2024-02-01

179
papers

2,717
citations

218677

26
h-index

302126

39
g-index

185
all docs

185
docs citations

185
times ranked

2224
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-alcoholic fatty liver disease and thrombocytopenia IV: its association with granulocytopenia. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, 44, 491-496.	0.2	5
2	Outpatient allogeneic hematopoietic stem-cell transplantation: a review. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210807.	2.5	6
3	Long term survival in multiple myeloma: a single institution experience in underprivileged circumstances. <i>Leukemia and Lymphoma</i> , 2022, 63, 1236-1241.	1.3	2
4	High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma. <i>Hematology</i> , 2022, 27, 449-455.	1.5	4
5	miRNAs in multiple sclerosis: A clinical approach. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103835.	2.0	2
6	Primary Thrombophilia XVII: A Narrative Review of Sticky Platelet Syndrome in México. <i>Journal of Clinical Medicine</i> , 2022, 11, 4100.	2.4	2
7	Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 40-44.	2.3	5
8	The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-México Program: A Myriad of Experiences and Knowledge. <i>Frontiers in Neurology</i> , 2021, 12, 647425.	2.4	15
9	Letter to the Editor: Bien plus Encore: Haplo Indeed Can be Completed on an Outpatient Basis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 519-520.	1.2	4
10	Treating Acute Leukemia During the COVID-19 Pandemic in an Environment With Limited Resources: A Multicenter Experience in Four Latin American Countries. <i>JCO Global Oncology</i> , 2021, 7, 577-584.	1.8	13
11	Prescription Patterns of Daratumumab in Patients with Multiple Myeloma in Underprivileged Circumstances: A Multicenter Experience in Mexico. <i>Archives of Medical Research</i> , 2021, 52, 627-634.	3.3	2
12	Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: Real-world data from a single center. <i>World Journal of Clinical Oncology</i> , 2021, 12, 800-807.	2.3	3
13	Primary Thrombophilia XVI: A Look at the Genotype of the Sticky Platelet Syndrome Phenotype. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110442.	1.7	2
14	Demonstración de Factibilidad: Nonalcoholic Fatty Liver Disease May Cause Thrombocytopenia. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, , .	2.7	1
15	<i>Helicobacter pylori</i> antibodies and multiple sclerosis: a single-center study and a short review of the literature. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2021, 57, .	1.0	0
16	Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study. <i>Leukemia and Lymphoma</i> , 2020, 61, 3112-3119.	1.3	4
17	Lessons learned starting a bone marrow transplantation programme in a resource-constrained setting. <i>Lancet Haematology</i> , 2020, 7, e509-e510.	4.6	14
18	Up to half of patients diagnosed with chronic lymphocytic leukemia in México may not require treatment. <i>Hematology</i> , 2020, 25, 156-159.	1.5	3

#	ARTICLE	IF	CITATIONS
19	Treatment of Persons with Multiple Myeloma in Underprivileged Circumstances: Real-World Data from a Single Institution. <i>Acta Haematologica</i> , 2020, 143, 552-558.	1.4	9
20	Glomerular Filtration Rate in Patients with Multiple Sclerosis Undergoing Stem Cell Transplantation and Treated with Cyclophosphamide. <i>Laboratory Medicine</i> , 2019, 50, 42-46.	1.2	6
21	Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center. <i>Clinical and Experimental Immunology</i> , 2019, 198, 351-358.	2.6	13
22	Primary thrombophilia XV: antithrombotic treatment of sticky platelet syndrome worldwide. <i>Annals of Blood</i> , 2019, 4, 15-15.	0.4	6
23	Determine safety of outpatient chemotherapy and autotransplants using refrigerated, non-frozen grafts in persons with multiple sclerosis. <i>Clinical Transplantation</i> , 2019, 33, e13567.	1.6	7
24	Primary Thrombophilia XIV: Worldwide Identification of Sticky Platelet Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 423-428.	2.7	8
25	Primary Thrombophilia in Mexico XIII: Localization of the Thrombotic Events in Mexican Mestizos With the Sticky Platelet Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961984170.	1.7	6
26	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. <i>Annals of Hematology</i> , 2019, 98, 941-949.	1.8	9
27	Nonalcoholic Fatty Liver Disease and Thrombocytopenia III: Its Association With Insulin Resistance. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961988869.	1.7	7
28	Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e43-e50.	0.4	13
29	A unique case of donor cell myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1839-1841.	1.3	1
30	Factors Involved in the Selection of Treatment in Patients with Hematological Malignancies. <i>Acta Haematologica</i> , 2019, 141, 54-54.	1.4	4
31	The big freeze may be over: a contracting universe for cryopreservation?. <i>Bone Marrow Transplantation</i> , 2018, 53, 947-948.	2.4	10
32	Modifications to the "Classical" Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis: A Less Toxic Approach is Feasible and Improves the Neurological Condition. A Mexican Perspective. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S125-S126.	2.0	2
33	Whither the Bone Marrow Transplantation in Multiple Myeloma?. <i>Acta Haematologica</i> , 2018, 139, 131-131.	1.4	0
34	Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas. <i>Bone Marrow Transplantation</i> , 2018, 53, 457-460.	2.4	28
35	Autotransplantations Without Cryopreservation. <i>Journal of Global Oncology</i> , 2018, 4, 1-1.	0.5	4
36	Geographic Hematology: Some Observations in Mexico. <i>Acta Haematologica</i> , 2018, 140, 114-120.	1.4	11

#	ARTICLE	IF	CITATIONS
37	Metabolomic profile of insulin resistance in patients with multiple sclerosis is associated to the severity of the disease. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 316-321.	2.0	29
38	More on the thrombocytopenia of the non-alcoholic fatty liver disease. <i>Hematology</i> , 2017, 22, 316-319.	1.5	6
39	A Feasibility Study of the Full Outpatient Conduction of Hematopoietic Transplants in Persons with Multiple Sclerosis Employing Autologous Non-Cryopreserved Peripheral Blood Stem Cells. <i>Acta Haematologica</i> , 2017, 137, 214-219.	1.4	27
40	Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective. <i>Expert Review of Hematology</i> , 2017, 10, 809-819.	2.2	7
41	Economic Challenges in Hematopoietic Cell Transplantation: How Will New and Established Programs Face the Growing Costs?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1815-1816.	2.0	6
42	Primary Thrombophilia in MÃ©xico XI: Activated Protein C Resistance Phenotypes are Multifactorial. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 375-379.	0.6	1
43	Observational study of multiple myeloma in Latin America. <i>Annals of Hematology</i> , 2017, 96, 65-72.	1.8	29
44	Acute Leukemia Characteristics are Different Around the World: the Mexican Perspective. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 46-51.	0.4	28
45	Primary thrombophilia in MÃ©xico XII: Miscarriages are more frequent in persons with the Sticky Platelet Syndrome (SPS). <i>Turkish Journal of Haematology</i> , 2017, 34, 239-243.	0.5	12
46	Importance of Nutrition in the Treatment of Leukemia in Children and Adolescents. <i>Archives of Medical Research</i> , 2016, 47, 585-592.	3.3	32
47	A New Breed in the Teaching of Medicine: Paid Lecturers, Trainers or Speakers?. <i>Acta Haematologica</i> , 2016, 135, 191-192.	1.4	2
48	The treatment of CML at an environment with limited resources. <i>Hematology</i> , 2016, 21, 576-582.	1.5	11
49	The Changing Pattern of Admission of Allograft Patients to the Intensive Care Unit. <i>Acta Haematologica</i> , 2016, 135, 70-71.	1.4	1
50	Stem Cell Transplantation Procedures Are Becoming Affordable for Individuals Living in Developing (Middle-Income) Countries. <i>Acta Haematologica</i> , 2016, 135, 79-80.	1.4	6
51	Staunching the rising costs of haematological health care. <i>Lancet Haematology</i> , the, 2016, 3, e455.	4.6	8
52	Clearance of donor cell leukemia by means of graft versus leukemia effect: A case report. <i>Hematology</i> , 2016, 21, 470-473.	1.5	2
53	Advances in the diagnosis and treatment of acute and chronic leukemia in Mexico. <i>Salud Publica De Mexico</i> , 2016, 58, 291-295.	0.4	5
54	Mexican Biosimilar Filgrastim for Autologous Hematopoietic Stem Cell Mobilization and Transplantation. <i>Revista De Investigacion Clinica</i> , 2016, 68, 181-3.	0.4	6

#	ARTICLE	IF	CITATIONS
55	The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2015, 8, 16-21.	0.9	13
56	Primary Thrombophilia in México X. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 91-95.	1.7	18
57	Publications of bone marrow transplants in Latin America. A report of the Latin American Group of Bone Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1130-1131.	2.4	9
58	Reduced-intensity stem cell allografting for PNH patients in the eculizumab era: The Mexican experience. <i>Hematology</i> , 2015, 20, 263-266.	1.5	6
59	Haploidentical Bone Marrow Transplantation in 2015 and Beyond. <i>Current Oncology Reports</i> , 2015, 17, 57.	4.0	10
60	Sticky Platelet Syndrome: History and Future Perspectives. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 526-534.	2.7	32
61	Secondary malignancies after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning and outpatient conduction. <i>Hematology</i> , 2014, 19, 435-440.	1.5	6
62	Nonalcoholic Fatty Liver Disease May Cause Thrombocytopenia. <i>Acta Haematologica</i> , 2014, 132, 159-162.	1.4	15
63	Diagnosing and treating mixed phenotype acute leukemia: a multicenter 10-year experience in México. <i>Annals of Hematology</i> , 2014, 93, 595-601.	1.8	24
64	Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. <i>Annals of Hematology</i> , 2014, 93, 2001-2010.	1.8	58
65	Cell-Freezing Devices Are Not Strictly Needed to Start an Autologous Hematopoietic Transplantation Program: Non-Cryopreserved Peripheral Blood Stem Cells Can be Used to Restore Hematopoiesis after High Dose Chemotherapy: A Multicenter Experience in 268 Autografts in Patients with Multiple Myeloma or Lymphoma. Study on Behalf of the Latin-American Bone Marrow Transplantation Group (LABMT). <i>Blood</i> , 2014, 124, 849-849.	1.4	7
66	Paroxysmal nocturnal hemoglobinuria in México: a 30-year, single institution experience. <i>Revista De Investigacion Clinica</i> , 2014, 66, 12-6.	0.4	3
67	Simultaneous romiplostin, eltrombopag, and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydrocortisone, splenectomy, intravenous IgG, and rituximab. <i>Hematology</i> , 2013, 18, 175-177.	1.5	7
68	The sticky platelet syndrome. <i>Hematology</i> , 2013, 18, 230-232.	1.5	11
69	In pursuit of the graft-versus-myeloma effect: A single institution experience. <i>Hematology</i> , 2013, 18, 89-92.	1.5	3
70	Primary thrombophilia in Mexico IX. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 689-692.	1.7	15
71	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. <i>Blood</i> , 2013, 121, 1935-1943.	1.4	96
72	Iron deficiency anemia in low- and middle-income countries. <i>Blood</i> , 2013, 122, 2289-2289.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin's lymphoma in a developing country?. <i>Hematology</i> , 2012, 17, 193-197.	1.5	6
74	Moderate hyperprolactinemia is associated with survival in patients with acute graft-versus-host disease after allogeneic stem cell transplantation. <i>Hematology</i> , 2012, 17, 85-92.	1.5	5
75	Treatment of hairy cell leukemia: long-term results in a developing country. <i>Hematology</i> , 2012, 17, 140-143.	1.5	9
76	A Mexican way to cope with stem cell grafting. <i>Hematology</i> , 2012, 17, s195-s197.	1.5	22
77	CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value. <i>Hematology</i> , 2012, 17, 66-70.	1.5	12
78	Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting. <i>American Journal of Hematology</i> , 2012, 87, 941-941.	4.1	6
79	Antibodies in the Treatment of Aplastic Anemia. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2012, 60, 99-106.	2.3	12
80	On the prevalence and genetic predisposition of monoclonal gammopathy of undetermined significance (MGUS). <i>International Journal of Hematology</i> , 2012, 96, 144-145.	1.6	2
81	Reduced-Intensity Allografting in Childhood Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 439-440.	2.0	2
82	Low incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral blood stem cell transplantation employing a reduced-intensity conditioning. <i>European Journal of Haematology</i> , 2011, 87, 521-530.	2.2	13
83	Outcome of adults with acute lymphoblastic leukemia treated with a pediatric-inspired therapy: a single institution experience. <i>Leukemia and Lymphoma</i> , 2011, 52, 314-316.	1.3	20
84	Romiplostin may revert the thrombocytopenia in graft-versus-host disease. <i>Hematology</i> , 2011, 16, 108-109.	1.5	7
85	Long-term results of placental blood allografting using reduced-intensity conditioning: multicenter experience in a developing country. <i>Hematology</i> , 2011, 16, 155-159.	1.5	7
86	Core binding factor acute myeloid leukemia (CBF-AML) in Mexico: a single institution experience. <i>Revista De Investigacion Clinica</i> , 2011, 63, 25-30.	0.4	2
87	Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. <i>Annals of Hematology</i> , 2010, 89, 299-303.	1.8	25
88	Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. <i>Annals of Hematology</i> , 2010, 89, 1045-1052.	1.8	10
89	POOR HEMOPOIETIC STEM CELL MOBILIZERS IN MULTIPLE MYELOMA : A SINGLE INSTITUTION EXPERIENCE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010016.	1.3	3
90	Whither the bone marrow transplant?. <i>Hematology</i> , 2010, 15, 1-3.	1.5	13

#	ARTICLE	IF	CITATIONS
91	The flow-cytometric DNA content of the plasma cells of patients with multiple myeloma is a prognostic factor: a single institution experience. <i>Hematology</i> , 2010, 15, 378-381.	1.5	6
92	Molecular characterization of chronic myeloproliferative neoplasias in México. <i>Hematology</i> , 2009, 14, 261-265.	1.5	1
93	A simplified method for stem cell autografting in multiple myeloma: a single institution experience. <i>Bone Marrow Transplantation</i> , 2009, 44, 715-719.	2.4	44
94	Dimethyl Sulfoxide-Induced Toxicity in Cord Blood Stem Cell Transplantation: Report of Three Cases and Review of the Literature. <i>Acta Haematologica</i> , 2009, 122, 1-5.	1.4	69
95	Donor-derived hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 1712-1714.	1.3	3
96	A single apheresis procedure in the donor may be enough to complete an allograft using the "Mexican method" of non-ablative allografting. <i>Blood Transfusion</i> , 2009, 7, 127-31.	0.4	4
97	Experience in developing countries. <i>Pediatric Blood and Cancer</i> , 2008, 50, 517-517.	1.5	0
98	Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?. <i>Bone Marrow Transplantation</i> , 2008, 42, 23-28.	2.4	47
99	Alemtuzumab for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 10-15.	2.0	72
100	Alemtuzumab-Induced Resolution of Refractory Cutaneous Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 7-9.	2.0	17
101	Re: Alemtuzumab-Induced Resolution of Pulmonary Noninfectious Complications in a Patient with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1434-1435.	2.0	3
102	Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance. <i>Mayo Clinic Proceedings</i> , 2008, 83, 601-602.	3.0	6
103	Primary thrombophilia in México VII: the V617F mutation of JAK2 is not a frequent cause of thrombosis. <i>Hematology</i> , 2008, 13, 244-246.	1.5	9
104	Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance. <i>Mayo Clinic Proceedings</i> , 2008, 83, 601-602.	3.0	11
105	Ineffectiveness of oral iron hydroxide polymaltose in iron-deficiency anemia. <i>Hematology</i> , 2007, 12, 255-256.	1.5	23
106	Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR C677T allele in Mexico. <i>Hematology</i> , 2007, 12, 387-391.	1.5	36
107	Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. <i>Hematology</i> , 2007, 12, 193-197.	1.5	10
108	Donor cell leukemia: A critical review. <i>Leukemia and Lymphoma</i> , 2007, 48, 25-38.	1.3	30

#	ARTICLE	IF	CITATIONS
109	Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia. <i>American Journal of Hematology</i> , 2007, 82, 400-402.	4.1	8
110	Outpatient allografting using non-myeloablative conditioning: the Mexican experience. <i>Bone Marrow Transplantation</i> , 2007, 40, 119-123.	2.4	24
111	Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study. <i>Bone Marrow Transplantation</i> , 2007, 40, 535-539.	2.4	29
112	Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan. <i>Annals of Hematology</i> , 2007, 86, 277-282.	1.8	13
113	Minimal Residual Disease Testing in Acute Leukemia by Flow Cytometry Immunophenotyping: Prognostic Significance. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2007, 13, 22-26.	1.2	7
114	Donor cell leukemia after non-myeloablative allogeneic stem cell transplantation: A single institution experience. <i>Leukemia and Lymphoma</i> , 2006, 47, 1952-1955.	1.3	22
115	Transient mixed chimerism after stem cell transplantation can induce durable molecular complete remissions in chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 2590-2592.	1.3	2
116	Altered Functional Status of the Hypothalamic Dopaminergic Tone in Patients with Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Study. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 566-572.	2.0	7
117	Nephrotic syndrome after non-myeloablative stem cell transplantation. <i>British Journal of Haematology</i> , 2006, 132, 801-801.	2.5	6
118	HFE-Codon 63/282 (H63D/C282Y) Gene Variants in Mexican Mestizos Are Not Risk Factors for Leukemia. <i>Archives of Medical Research</i> , 2006, 37, 65-67.	3.3	3
119	Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: The Mexican experience. <i>American Journal of Hematology</i> , 2006, 81, 157-161.	4.1	42
120	t(8;21) (q22;q22) Acute myelogenous leukemia in México: A single institution experience. <i>Hematology</i> , 2006, 11, 235-238.	1.5	7
121	Umbilical cord blood transplantation using non-myeloablative conditioning: The Mexican experience. <i>Hematology</i> , 2006, 11, 355-359.	1.5	10
122	Second allogeneic peripheral blood stem cell transplants with reduced-intensity conditioning. <i>Revista De Investigacion Clinica</i> , 2006, 58, 34-8.	0.4	6
123	The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México. <i>Revista De Investigacion Clinica</i> , 2006, 58, 458-61.	0.4	2
124	Extramedullary Leukemic Relapses following Hematopoietic Stem Cell Transplantation with Nonmyeloablative Conditioning. <i>International Journal of Hematology</i> , 2005, 82, 262-265.	1.6	14
125	Significance of one human leukocyte antigen mismatch on outcome of nonmyeloablative allogeneic stem cell transplantation from related donors using the Mexican schedule. <i>Bone Marrow Transplantation</i> , 2005, 35, 335-339.	2.4	3
126	Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. <i>Bone Marrow Transplantation</i> , 2005, 36, 715-720.	2.4	14

#	ARTICLE	IF	CITATIONS
127	The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. <i>Bone Marrow Transplantation</i> , 2005, 36, 1043-1047.	2.4	39
128	Primary thrombophilia in Mexico. V. A comprehensive prospective study indicates that most cases are multifactorial. <i>American Journal of Hematology</i> , 2005, 78, 21-26.	4.1	31
129	Haematopoietic stem cell transplantation to treat aplastic anaemia. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 617-626.	3.1	12
130	Gilbert's syndrome disclosed during the treatment of hematological malignancies. <i>Hematology</i> , 2005, 10, 59-60.	1.5	4
131	The Mexican approach to conduct allogeneic stem cell transplantation: Braking dogmata and facing the Matthew effect. <i>Hematology</i> , 2005, 10, 154-160.	1.5	9
132	Treatment of acute promyelocytic leukemia: a single institution experience. <i>Revista De Investigacion Clinica</i> , 2005, 57, 415-9.	0.4	3
133	Multiple Myeloma in Mexico: A 20-year experience at a single institution. <i>Archives of Medical Research</i> , 2004, 35, 163-167.	3.3	22
134	The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease. <i>American Journal of Hematology</i> , 2004, 75, 200-204.	4.1	9
135	Breaking dogmata to help patients: non-myeloablative haematopoietic stem cell transplantation. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 1693-1699.	3.1	15
136	Allogeneic Hematopoietic Stem Cell Transplantation with Non-Myeloablative Conditioning in Patients with Acute Myelogenous Leukemia Eligible for Conventional Allografting: A Prospective Study. <i>Leukemia and Lymphoma</i> , 2004, 45, 1191-1195.	1.3	28
137	More on Geographic Hematology: The Breakpoint Cluster Regions of the PML/RAR α Fusion Gene in Mexican Mestizo Patients with Promyelocytic Leukemia are Different from Those in Caucasians. <i>Leukemia and Lymphoma</i> , 2004, 45, 1365-1368.	1.3	33
138	Primary thrombophilia in Mexico IV: frequency of the Leiden, Cambridge, Hong Kong, Liverpool and HR2 haplotype polymorphisms in the factor V gene of a group of thrombophilic Mexican Mestizo patients. <i>Revista De Investigacion Clinica</i> , 2004, 56, 600-4.	0.4	4
139	Frequencies of the breakpoint cluster region types of the BCR/ABL fusion gene in Mexican Mestizo patients with chronic myelogenous leukemia. <i>Revista De Investigacion Clinica</i> , 2004, 56, 605-8.	0.4	6
140	The Mexican Approach to Conduct Nonmyeloablative Stem Cell Transplantation Should Not Be Overlooked. <i>International Journal of Hematology</i> , 2003, 77, 526-527.	1.6	8
141	Non-myeloablative bone marrow transplantation. <i>Archives of Medical Research</i> , 2003, 34, 554-557.	3.3	5
142	Successful Allogeneic Stem Cell Transplantation with Nonmyeloablative Conditioning in Patients with Relapsed Hodgkin's Disease Following Autologous Stem Cell Transplantation. <i>Archives of Medical Research</i> , 2003, 34, 242-245.	3.3	8
143	Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 157-161.	2.0	51
144	Results of an Autologous Noncryopreserved, Unmanipulated Peripheral Blood Hematopoietic Stem Cell Transplant Program: A Single-Institution, 10-Year Experience. <i>Acta Haematologica</i> , 2003, 110, 179-183.	1.4	38

#	ARTICLE	IF	CITATIONS
145	Long-Term Results of the Immunosuppressive Treatment of Patients with Severe Acquired Aplastic Anemia: A Single Institution Study. <i>Acta Haematologica</i> , 2003, 110, 184-187.	1.4	12
146	Decreased Transfusion Requirements in Patients Given Stem Cell Allografts Using a Non-myeloablative Conditioning Regimen: A Single Institution Experience. <i>Hematology</i> , 2003, 8, 151-154.	1.5	11
147	Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 157-161.	2.0	41
148	A critical review of the prognostic value of the nutritional status at diagnosis in the outcome of therapy of children with acute lymphoblastic leukemia. <i>Revista De Investigacion Clinica</i> , 2003, 55, 31-5.	0.4	41
149	Primary Thrombophilia in Mexico III: A Prospective Study of the Sticky Platelet Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2002, 8, 273-277.	1.7	20
150	Follow up of Hemopoietic Chimerism in Individuals Given Allogeneic Hemopoietic Stem Cell Allografts Using an Immunosuppressive, Non-myeloablative Conditioning Regimen: a Prospective Study in a Single Institution. <i>Leukemia and Lymphoma</i> , 2002, 43, 1509-1511.	1.3	15
151	No Cytomegalovirus-related Deaths After Non-ablative Stem Cell Allografts. <i>Hematology</i> , 2002, 7, 95-99.	1.5	11
152	An Addition to Geographic Hematology: Chronic Myeloproliferative Diseases Are Infrequent in Mexican Mestizos. <i>International Journal of Hematology</i> , 2002, 75, 499-502.	1.6	7
153	Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: Results of the Mexican approach. <i>International Journal of Hematology</i> , 2002, 76, 376-379.	1.6	28
154	Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. <i>Haematologica</i> , 2002, 87, 894-6.	3.5	22
155	Features of the Engraftment of Allogeneic Hematopoietic Stem Cells Using Reduced-Intensity Conditioning Regimens. <i>Leukemia and Lymphoma</i> , 2001, 42, 145-150.	1.3	13
156	Decreased dopaminergic tone and increased basal bioactive prolactin in men with human immunodeficiency virus infection. <i>Clinical Endocrinology</i> , 2001, 54, 731-738.	2.4	17
157	Primary thrombophilia in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos. <i>American Journal of Hematology</i> , 2001, 66, 28-31.	4.1	34
158	Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. <i>American Journal of Hematology</i> , 2001, 66, 241-244.	4.1	70
159	“The Mexican approach”™ to conduct NST. <i>European Journal of Haematology</i> , 2001, 67, 335-335.	2.2	5
160	SIMPLIFICATION, NOT DEMYSTIFICATION NOR TRIVIALIZATION OF STEM CELL TRANSPLANTATION. <i>Haematologica</i> , 2001, 86, E07.	3.5	4
161	Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases. <i>Bone Marrow Transplantation</i> , 2000, 25, 131-133.	2.4	57
162	Analysis of HFE-Codon 63/282 (H63D/C282Y) Gene Variants in Mexican Mestizos. <i>Archives of Medical Research</i> , 2000, 31, 422-424.	3.3	6

#	ARTICLE	IF	CITATIONS
163	PML/RAR \pm (+) Hypergranular Acute Promyelocytic Leukemia (M3) Developing into an M3 Acute Myelocytic Leukemia without PML/RAR \pm . <i>Acta Haematologica</i> , 2000, 104, 124-127.	1.4	1
164	Assessment of residual disease in acute leukemia by means of polymerase chain reaction. <i>Revista De Investigacion Clinica</i> , 2000, 52, 118-24.	0.4	2
165	Waldenström's macroglobulinemia is infrequent in Mexican Mestizos: experience of a hematological diseases referral center. <i>Revista De Investigacion Clinica</i> , 2000, 52, 497-9.	0.4	11
166	Non-Cryopreserved Unmanipulated Hematopoietic Peripheral Blood Stem Cell Autotransplant Program. <i>Archives of Medical Research</i> , 1999, 30, 380-384.	3.3	22
167	Primary thrombophilia in Mexico: A prospective study. , 1999, 60, 1-5.		16
168	Chronic lymphocytic leukemia is infrequent in Mexican mestizos. <i>International Journal of Hematology</i> , 1999, 69, 253-5.	1.6	9
169	Nutritional status and socio-economic conditions as prognostic factors in the outcome of therapy in childhood acute lymphoblastic leukemia. , 1998, 78, 52-55.		30
170	Non-cryopreserved peripheral blood stem cells autotransplants for hematological malignancies can be performed entirely on an outpatient basis. , 1998, 58, 161-164.		31
171	Nutritional status and socio-economic conditions as prognostic factors in the outcome of therapy in childhood acute lymphoblastic leukemia. <i>International Journal of Cancer</i> , 1998, 78, 52-55.	5.1	4
172	Hairy cell leukemia is infrequent in México and has a geographic distribution. , 1996, 52, 316-318.		15
173	Filgrastim-mobilized peripheral blood stem cells can be stored at 4 degrees and used in autografts to rescue high-dose chemotherapy. <i>American Journal of Hematology</i> , 1995, 48, 100-103.	4.1	40
174	Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia (AML) is feasible: a multicentre study. <i>European Journal of Haematology</i> , 1995, 54, 18-20.	2.2	28
175	Leukaemia and nutrition I: Malnutrition is an adverse prognostic factor in the outcome of treatment of patients with standard-risk acute lymphoblastic leukaemia. <i>Leukemia Research</i> , 1989, 13, 899-906.	0.8	94
176	Low Doses of High-Potency Antithymocyte Globulin (ATG) in Severe Aplastic Anemia: Experience with the Mexican ATG. <i>Acta Haematologica</i> , 1989, 81, 70-74.	1.4	10
177	Lymphocyte subsets in patients with aplastic anemia. <i>American Journal of Hematology</i> , 1984, 16, 267-275.	4.1	14
178	Studies on lymphomata. III. Lymphomata, granulomata and tuberculosis. <i>Cancer</i> , 1983, 52, 258-262.	4.1	14
179	Red cell indices in normal adults residing at altitudes from sea level to 2670 meters. <i>American Journal of Hematology</i> , 1980, 8, 265-271.	4.1	46